We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Dra. Lynne Postovit - Associate Professor, Sawin-Baldwin Chair in Ovarian Cancer, Department of Oncology -Division of Experimental Oncology - University of Alberta - Canada
"Cell plasticity in cancer"
Tumours contain populations of cells with stem cell like properties, and these phenotypically plastic cells are responsible for cancer recurrence and metastatic potential. Stem cell-like populations are regulated by dynamic niches, characterized by specific growth factors and extracellular matrices, as well as biophysical features such low oxygen tensions. Moreover, a growing body of evidence suggests that cancer cells co-opt stem cell-associated regulatory networks in order to sustain plasticity. For example, we have discovered that an embryonic-associated protein called Nodal maintains stem cell phenotypes in cancer, and that it promotes classical hallmarks of cancer such as angiogenesis, chemotherapy resistance invasion and metastasis. We have also found that biophysical features of a growing tumour, in particular hypoxia, can promote tumour cell plasticity by up-regulating embryonic proteins like Nodal via a combinatorial mechanism involving alterations in bivalent histone modifications as well as selective mRNA translation. Finally, we have determined that these complex interactions can be confounded by genetic variability leading to the expression of unique proteoforms. By studying the mechanisms by which cancer cells acquire and sustain phenotypic plasticity, we may uncover novel targets for the prediction and prevention of tumour progression.
Host: Translational Molecular Pathology stefan.hummer@vhir.org
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.